

26th July 2022

- | | |
|---|--|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements), 2015 ("Listing Regulations")


Dear Sir/Madam,

Pursuant to Regulation 30 of the Listing Regulations and in reference to earlier intimations dated 13th November 2018, 8th February 2019, 3rd November 2021 and 12th January 2022, we hereby notify that InvaGen Pharmaceuticals Inc., wholly owned step-down subsidiary of the Company in USA has entered into a Share Repurchase Agreement on 25th July 2022 with Avenue Therapeutics, Inc. ("Avenue") and Fortress Biotech, Inc., for sale of 5,833,333 shares representing 25.93% of equity stake (on a fully diluted basis) held in Avenue for a consideration of USD 3 million and an additional amount upto USD 4 million on satisfaction of certain conditions.

The consideration amount is subject to completion of closing conditions and future financing by Avenue. On completion of the repurchase, Avenue shall cease to be an associate of the Company.

Please take the above information on record.

Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary



Prepared by: Mandar Kurghode

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.
P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-Mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380